A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1498651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Hongzhi Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of TB Diseases, Affiliated Infectious Diseases Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Tuberculosis, Lipopolysaccharides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Traditional lipoarabinomannan tests have limited sensitivity in HIV-negative individuals. Our aims were to compare chemiluminescence-based LAM (AIMLAM) and other diagnostic modalities in HIV-negative patients and to explore whether lymphocyte counts impact the sensitivity and costs of AIMLAM.
Methods
This is a prospective, cross-sectional, diagnostic accuracy study. Participants underwent testing with sputum acid-fast bacilli, sputum culture, GeneXpert, and AIMLAM. Their diagnostic efficiency and cost-effectiveness alone or under different lymphocyte count categories was evaluated.
Results
Using MRS as a reference, the sensitivities of different diagnostic methods were as follows: sputum smear 27.43%, sputum culture 45.13%, GeneXpert 74.34%, and AIMLAM 71.68%. Patients with lymphocyte counts <0.8 × 10 9 /L were significantly more likely to have a positive AIMLAM result (OR = 9.431, 95% CI: 2.659–33.447, P = 0.001). The sensitivity of AIMLAM in patients with lymphocyte counts <0.8 × 10 9 /L reached 93.02%. The overall cost of AIMLAM to detect a positive TB case was $129.82, lower than sputum culture ($136.10) and GeneXpert ($180.27). For patients with lymphocyte counts <0.8 × 10 9 /L, the cost of AIMLAM was further reduced to $67.84 (a 47.74% decrease), which was lower than GeneXpert ($111.65) and sputum culture ($94.28).
Conclusion
AIMLAM showed promising diagnostic performance in HIV-negative patients. Stratifying patients using lymphocyte cell counting lifted the sensitivity and lowered the cost of LAM, offering a novel diagnostic strategy for tuberculosis in resource-limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of TB Diseases, Affiliated Infectious Diseases Hospital of Zhengzhou University, Zhengzhou, China.
- Department of TB Diseases, Henan Infectious Diseases Hospital, Zhengzhou, China.
- Department of TB Diseases, The Sixth People's Hospital of Zhengzhou, Zhengzhou, China.
Zitieren
APA
Li, H., Gao, X., Liu, D., Li, Z., & Li, J. (2025). A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1498651
Vancouver
Li H, Gao X, Liu D, Li Z, Li J. A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1498651
BibTeX
@article{Li2025,
author = {Li, Hongzhi and Gao, Xian and Liu, Dandan and Li, Zhe and Li, Jing},
title = {A new strategy improving TB diagnosis: stratified urine LAM test based on lymphocyte counts},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1498651}
}
EUVIMED